特发性正常压力脑积水分流术的安慰剂对照有效性:一项随机先导试验
这项多中心随机先导试验将18例特发性正常压力脑积水患者随机分为开放分流组(Codman Certas Plus阀设为4)与安慰剂组(设为8,即虚拟关闭),患者和评估者均设盲。4个月时开放分流组步速增加0.28±0.28 m/s,安慰剂组增加0.04±0.17 m/s,估计治疗差异为0.22 m/s(95%CI -0.02至0.46,P=0.071),仅呈步速改善趋势;开放分流组膀胱过度活动症状 bother 问卷显著改善(P=0.007)。作者认为该试验证明了在特发性正常压力脑积水开展安慰剂对照试验的有效性、安全性和可行性。
要点
- 4个月时开放分流组步速增加0.28±0.28 m/s,安慰剂组增加0.04±0.17 m/s,治疗差异0.22 m/s(95%CI -0.02至0.46,P=0.071)。
- 开放分流组膀胱过度活动简表症状困扰问卷较安慰剂组显著改善(P=0.007)。
- 4个月的治疗延迟未降低后续对主动分流的反应,也未增加12个月时的不良事件率。
核心结论
- 这项多中心随机先导试验证明在特发性正常压力脑积水开展安慰剂对照试验具有有效性、安全性和可行性,并发现开放分流组步速改善优于安慰剂组的趋势。
研究设计与样本
- 多中心随机先导试验,共18例特发性正常压力脑积水患者,随机分入开放分流组(Codman Certas Plus阀设为4)或安慰剂组(设为8,即虚拟关闭),患者与评估者设盲。
- 主要结局为10米步速,次要结局包括膀胱控制、日常生活活动、抑郁和生活质量的功能量表;4个月评估后所有分流阀以盲法调至活跃设置并随访至分流后12个月。
主要发现
- 4个月评估时,开放分流组步速增加0.28±0.28 m/s,安慰剂组增加0.04±0.17 m/s,估计治疗差异为0.22 m/s(P=0.071,95%CI -0.02至0.46)。
- 膀胱过度活动简表症状困扰问卷在开放分流组较安慰剂组显著改善(P=0.007)。
- 4个月的治疗延迟未降低后续对主动分流的反应,也未增加12个月时的不良事件率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple prospective nonrandomized studies have shown 60% to 70% of patients with idiopathic normal pressure hydrocephalus (iNPH) improve with shunt surgery, but multicenter placebo-controlled trial data are necessary to determine its effectiveness. OBJECTIVE: To evaluate the effectiveness of cerebrospinal fluid shunting in iNPH through comparison of open vs placebo shunting groups at 4 months using a pilot study. METHODS: Patients were randomized to a Codman Certas Plus valve (Integra LifeSciences) set at 4 (open shunt group) or 8 ("virtual off"; placebo group). Patients and assessors were blinded to treatment group. The primary outcome measure was 10-m gait velocity. Secondary outcome measures included functional scales for bladder control, activities of daily living, depression, and quality of life. Immediately after 4-month evaluation, all shunts were adjusted in a blinded fashion to an active setting and followed to 12 months after shunting. RESULTS: A total of 18 patients were randomized. At the 4-month evaluation, gait velocity increased by 0.28 ± 0.28 m/s in the open shunt group vs 0.04 ± 0.17 m/s in the placebo group. The estimated treatment difference was 0.22 m/s ([ P = .071], 95% CI -0.02 to 0.46). Overactive Bladder Short Form symptom bother questionnaire significantly improved in open shunt vs placebo ( P = .007). The 4-month treatment delay did not reduce the subsequent response to active shunting, nor did it increase the adverse advents rate at 12 months. CONCLUSION: This multicenter, randomized pilot study demonstrates the effectiveness, safety, and feasibility of a placebo-controlled trial in iNPH, and found a trend suggesting gait velocity improves more in the open shunt group than in the placebo group.
引用
- Luciano M, Holubkov R, Williams MA, et al. Placebo-Controlled Effectiveness of Idiopathic Normal Pressure Hydrocephalus Shunting: A Randomized Pilot Trial. Neurosurgery. 2022. PMID: 36700738. doi:10.1227/neu.0000000000002225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。